Aerpio Pharmaceuticals, Inc. (ARPO) Stock

About Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in Blue Ash, Ohio, currently employs 27 full-time staff. The company's core mission revolves around the research and development of therapeutic solutions for ocular diseases. Its product pipeline is spearheaded by AKB-9778, with two additional programs, AKB-4924 and ARP-1536, also under development. AKB-9778 is a small molecule designed to activate the Tie-2 pathway, intended for the treatment of diabetic retinopathy (DR). AKB-4924, another candidate, functions as a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha) and is being investigated for its potential in treating inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody that targets the same pathway as AKB-9778. It operates by attaching to the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP), thereby inhibiting its interaction with Tie-2. As of April 14, 2017, Aerpio had successfully concluded a Phase II clinical trial for AKB-9778, which involved 144 patients with diabetic macular edema. By the same date, a Phase Ia clinical trial for AKB-4924 in healthy volunteers had also been completed.

Aerpio Pharmaceuticals, Inc. is headquartered in US.

Aerpio Pharmaceuticals, Inc. (ARPO) stock trades at $2.20 with a market capitalization of $53.67M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.31, reflecting a net loss over the last twelve months, price-to-book of 1.31, price-to-sales of 7.67. Over the past 52 weeks the stock has ranged between $2.16 and $49.80, and currently trades 95.6% below its 52-week high.

On profitability, Aerpio Pharmaceuticals, Inc. generates a return on equity (ROE) of -79.63% (negative, reflecting a net loss), return on capital employed of -105.62%, an operating margin of -1628.57%, a net profit margin of -300.00%.

Official website: www.aerpio.com